Question
Do BPA analogs have similar adverse effects as BPA on the structure and function of the developing mammalian ovary in vivo?
Introduction
Endocrine disrupting chemicals (EDCs) are compounds that can mimic or block the action of endogenous hormones in the body. These natural or synthetic chemicals can have major effects on development, fertility, and may be associated with cancers of the reproductive tract and mammary glands. Developmental exposures have been shown to induce meiotic defects and cause incorrect follicle formation in the developing ovary (Hunt & Hassold, 2008). These defects have long term implications and may adversely affect fertility and reproductive lifespan (Hunt et al., 2012). Developmental exposures seem to have a larger effect than exposures in adulthood, which can cause dose dependent and sex dependent changes to body weight (Rogers et al., 2013; Rubin & Soto, 2009). Bisphenol A (BPA) is an estrogen mimicking EDC that is commonly found in cans, plastic food and drink containers, dental materials, and receipts, leading to a relatively constant human exposure (Maffini et al., 2006). Recently, increasing numbers of animal studies have found that even at low levels BPA has detrimental effects on meiotic events and follicle formation in the developing ovary in both mouse and primate models (Hunt & Hassold, 2008; Hunt et al., 2012). All research looking into BPA’s effect on the developing ovary has been done using animal models because of ethical reasons that prevent the study of humans in this way.
BPA has been found to bind to estrogen receptors (ERα and ERβ) leading to dysfunction in the normal regulation of genes affected by these receptors. These receptors act as transcription factors that travel into the nucleus and cause changes to gene expression. ERα is expressed in theca cells (support cells for each follicle) and in the ovarian stroma during ovary development and in adulthood (Sar & Welsch, 1999). ERβ is expressed in granulosa cells of developing follicles (Sharma et al., 1999). Mouse knockouts of ERα (ERKO) and ERβ (ERBKO) have very different phenotypes. ERKOs have a phenotype where follicles appear to develop normally but then never ovulate or produce the correct outer covering Also, individuals have large hemorrhagic cysts, and stromal hyperplasia, as well as an excess of other circulating hormones like luteinizing hormone, testosterone, and estrogen (Abbot et al., 2006). This shows that ERα is necessary for regulation of the effect of other hormones in the ovary (Couse & Korach, 2001). ERBKO exhibits a phenotype where individuals are able to ovulate and produce pups but have fewer ovulation events and smaller litter sizes (Abbot et al., 2006). This shows that ERβ is necessary for mediation of estrogen’s effect on the ovary in ways related to maturation of follicles (Emmen et al., 2005). BPA’s effect on these receptors leads to changes in gene expression and regulation in the ovary (Zhou et al., 2008). BPA has an agonist effect on ERβ and has both an agonist and an antagonist effect on ERα (Kuiper et al., 1998; Hiroi et al., 1999). As the phenotypes of the ER knockouts are known, the overall phenotype of BPA exposed individuals can be split into changes caused by activation of ERβ and variable inactivation and activation of ERα. Activation of ERβ likely causes the misregulation of follicle maturation and formation, and BPA’s variable action on ERα likely causes differences in amount of stromal proliferation, and the potential presence of cysts and abnormally small oocytes.
Due to an increase in our understanding of the detrimental effects of BPA, analogs of BPA are beginning to be used in plastics manufacturing instead. Less is known about these derivatives of BPA, though recent studies have determined that many of these compounds have similar effects on estrogen receptors (Stossi et al., 2014). Two of the many BPA analogs that are commonly used are Tetrachlorobisphenol A (TCBPA) and Bisphenol S (BPS). TCBPA is an ERα agonist and BPS has agonistic effects on both receptors, with a higher activity in binding to ERβ (Table 1) (Li et al., 2010; Molina-Molina et al., 2013). As these compounds also have estrogenic effects, they will likely produce a phenotype in the developing ovary. If TCBPA and BPS have similar negative effects as BPA, then these analogs should not be used in manufacturing and other non-BPA-like alternatives should be developed. Currently the analogs are being used instead of BPA and manufacturers are calling the resulting plastics “BPA-free” (Yang et al., 2011).
EDC |
Effect on ERα |
Effect on ERβ |
BPA |
+/- |
+ |
TCBPA |
+ |
None |
BPS |
– |
– |
Table 1. Effect of BPA and two analogs on estrogen receptors ERα and ERβ. (+ signifies agonist effect and – signifies antagonist effect)
Hypotheses and Predictions
I hypothesize that both TCBPA and BPS will cause abnormal phenotypes in developing ovaries due to their action on estrogen receptors. I predict that TCBPA will likely have little effect on the formation of follicles but will cause decreases in the amount of stromal cells and an increase in the number of small, potentially non-functional, oocytes. Also, BPS will likely cause changes in follicle maturation and decrease stromal proliferation and increase the number of small oocytes.
Experimental approach
In order to investigate this question I will use a mouse model system. Benefits of a mouse model include ease of housing, lower expenses, quicker reproduction, and the ability to produce more than one offspring per pregnancy; however, there are some differences in pregnancy progression that make this model slightly less applicable to humans when compared to results from primate model studies. Hunt et al. (2012) found that primates exhibited a very similar phenotype in the developing ovary as mice when exposed to BPA, so there is merit to performing initial studies using a mouse model. As there are no other in vivo studies that look at the effects of TCBPA and BPS, using a mouse model will give a solid foundation for future primate studies that will be more applicable.
I will have four treatment groups: control (no treatment), BPA, TCBPA, and BPS. Each treatment group will consist of at least three female mice that will have a device that releases a continuous low level dose of either BPA, TCBPA, or BPS implanted subcutaneously. The implant consists of rubber tubing that contains the chemical (Hunt et al., 2012). A pilot study will be conducted to make sure that dosage levels are close to the normal serum concentrations found in humans (Hunt et al., 2012). Control females will have the device implanted but without the chemical additives. The implants will be inserted pre-pregnancy and dosage will continue throughout pregnancy. This method is the most similar to normal human exposure and may give the most realistic results (Hunt et al., 2012). The mice will then be mated and embryos will be harvested at mid and late gestation, the beginning of meiotic division and follicle formation respectively.
Female embryos will be studied to determine the effect of BPA analogs on chromosome behavior during meiosis and follicle formation in the developing ovary. The developing ovaries will be removed and sectioned in preparation for analysis at each gestational stage. Chromosome behaviour at early meiosis will be observed by performing immunofluorescence imaging of ovaries at mid gestation. SYCP3, CREST antiserum, and MLH1 will be tagged using fluorescent antibodies. SYCP3 is a symaptonemal complex protein, CREST interacts with centromeres, and MLH1 is a component of recombination events (Hunt et al., 2012). Synaptic defects can be observed by looking for increased number of recombination events, using points of concentrated MLH1 as a proxy. Chromosome associations can be observed by looking for clusters of CREST that mark centromeres interacting. Mice chromosomes are all telocentric, the centromere is near the telomere, so observation of end-to-end chromosome interactions are easy to see in this way. Tagging these proteins means that interactions can simply be counted and then compared. Follicle formation at late gestation will be investigated by using light microscopy with hematoxylin and eosin staining on serially sectioned ovaries and then observing or counting any follicular abnormalities that result. For instance, Hunt et al. (2012) counted multi-oocyte follicles and nests of unenclosed oocytes. Normally follicles only contain one oocyte and only a few, if any, oocytes are not enclosed within follicles. Control ovary immunofluorescence images and sections will be used to compare normal occurrence of abnormalities to the number seen in individuals treated with BPA, TCBPA, and BPS. Statistical analysis can then be performed to determine if the abnormalities are significantly higher in the treated groups than in the control group. These methods allow observation of chromosome behavior and ovarian structures after in vivo exposure to EDCs.
Possible outcomes
There are many possible outcomes for this experiment:
- TCBPA and BPS may not show gross phenotypic changes in the developing ovary. Further study may then be needed to identify if gene expression and hormone regulation are affected without causing large outward changes. This result may also be due to the dose given to the pregnant mice. If this result occurs, then different doses should be used to see if there is a point at which TCBPA and BPS do have an effect on the structure of a developing ovary.
- TCBPA and BPS may show novel phenotypes (when compared to BPA) in the developing ovary due to their different effects on the ERs. Depending on the degree of effect, there may be variation in the phenotype produced. These phenotypes will likely be in chromosome behaviour and follicle formation. As stated in my prediction, I think that TCBPA will cause changes in the number of stromal cells, leading to a decrease in ovary size, and an increase in the number of abnormally small oocytes that may affect future reproduction. BPS will likely cause changes in follicle formation and maturation, as well as decrease stromal proliferation and increase the number of small oocytes.
- TCBPA and BPS may show phenotypes in the developing ovary that are similar to those of BPA. This may be due to other unknown effects that the new chemicals may have on regulation of ovary growth and maturation. The severity of the phenotype from the analogs may differ from those produced by BPA because of different levels of activity when binding to the ERs or to other receptors.
Lay person summary
Hormones are very important molecules in the normal growth and function of male and female reproductive tracts. Natural and synthetic chemicals can mimic the function of hormones in the body by interacting with normal hormone pathways; these chemicals are called endocrine disrupting chemicals (EDCs). BPA is a chemical that is used to make plastics and other materials found in food and drink containers, the inside of cans, and receipts. In recent years, this chemical has been found to be an EDC. BPA mimics the function of estrogen and as such has detrimental effects on the developing ovary, where the correct levels of estrogen is important for proper growth. More recently, chemicals derived from BPA (BPA analogs) have started to be used by manufacturing companies instead of BPA, due to the increasing evidence for health concern; however, little is known about the effects of the analogs on development. I will perform an experiment on mice because of ethical constraints that prevent the study of human developing embryos. I will expose female mice to continuous low levels of BPA and two analogs, TCBPA (Tetrachlorobisphenol A) and BPS (Bisphenol S), throughout pregnancy. I will then observe the structure of the embryos’ developing ovaries using techniques that allow observation of how the chromosomes interact and how the ovaries’ cells develop. This topic is interesting because these compounds could have detrimental effects on human reproduction and fertility in the future, as the next generation of humans is being born to mothers that have been exposed to BPA, TCBPA, BPS, and other analogs.
Literature cited
Abbott, D. H., Padmanabhan, V., & Dumesic, D. A. (2006). Contributions of androgen and estrogen to fetal programming of ovarian dysfunction. Reprod Biol Endocrinol, 4(17), i0006-3363.
Couse, J. F., & Korach, K. S. (2001). Contrasting phenotypes in reproductive tissues of female estrogen receptor null mice. Annals of the New York Academy of Sciences, 948(1), 1-8.
Emmen, J. M., Couse, J. F., Elmore, S. A., Yates, M. M., Kissling, G. E., & Korach, K. S. (2005). In vitro growth and ovulation of follicles from ovaries of estrogen receptor (ER) α and ERβ null mice indicate a role for ERβ in follicular maturation. Endocrinology, 146(6), 2817-2826.
Hiroi, H., Tsutsumi, O., Momoeda, M., Takai, Y., Osuga, Y., & Taketani, Y. (1999). Differential interactions of Bisphenol A and 17β-estradiol with estrogen receptor α (ERα) and ERβ. Endocrine journal, 46(6), 773-778.
Hunt, P. A., & Hassold, T. J. (2008). Human female meiosis: what makes a good egg go bad?. Trends in Genetics, 24(2), 86-93.
Hunt, P. A., Lawson, C., Gieske, M., Murdoch, B., Smith, H., Marre, A., … & VandeVoort, C. A. (2012). Bisphenol A alters early oogenesis and follicle formation in the fetal ovary of the rhesus monkey. Proceedings of the National Academy of Sciences, 109(43), 17525-17530.
Kuiper, G. G., Lemmen, J. G., Carlsson, B. O., Corton, J. C., Safe, S. H., van der Saag, P. T., … & Gustafsson, J. A. (1998). Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor β. Endocrinology, 139(10), 4252-4263.
Li, J., Ma, M., & Wang, Z. (2010). In vitro profiling of endocrine disrupting effects of phenols. Toxicology in vitro, 24(1), 201-207.
Maffini, M. V., Rubin, B. S., Sonnenschein, C., & Soto, A. M. (2006). Endocrine disruptors and reproductive health: the case of bisphenol-A. Molecular and cellular endocrinology, 254, 179-186.
Molina-Molina, J. M., Amaya, E., Grimaldi, M., Sáenz, J. M., Real, M., Fernández, M. F., … & Olea, N. (2013). In vitro study on the agonistic and antagonistic activities of bisphenol-S and other bisphenol-A congeners and derivatives via nuclear receptors. Toxicology and applied pharmacology, 272(1), 127-136.
Rogers, J. A., Metz, L., & Yong, V. W. (2013). Review: Endocrine disrupting chemicals and immune responses: a focus on bisphenol-A and its potential mechanisms. Molecular immunology, 53(4), 421-430.
Rubin, B. S., & Soto, A. M. (2009). Bisphenol A: Perinatal exposure and body weight. Molecular and cellular endocrinology, 304(1), 55-62.
Sar, M., & Welsch, F. (1999). Differential expression of estrogen receptor-β and estrogen receptor-α in the rat ovary. Endocrinology, 140(2), 963-971.
Sharma, S. C., Clemens, J. W., Pisarska, M. D., & Richards, J. S. (1999). Expression and Function of Estrogen Receptor Subtypes in Granulosa Cells: Regulation by Estradiol and Forskolin 1. Endocrinology, 140(9), 4320-4334.
Stossi, F., Bolt, M. J., Ashcroft, F. J., Lamerdin, J. E., Melnick, J. S., Powell, R. T., … & Mancini, M. A. (2014). Defining estrogenic mechanisms of bisphenol A analogs through high throughput microscopy-based contextual assays. Chemistry & biology, 21(6), 743-753.
Yang, C. Z., Yaniger, S. I., Jordan, V. C., Klein, D. J., & Bittner, G. D. (2011). Most plastic products release estrogenic chemicals: a potential health problem that can be solved. Environmental Health Perspectives, 119(7), 989.
Zhou, W., Liu, J., Liao, L., Han, S., & Liu, J. (2008). Effect of bisphenol A on steroid hormone production in rat ovarian theca-interstitial and granulosa cells. Molecular and cellular endocrinology, 283(1), 12-18.